|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Registry and Statistics, . Cancer
Statistics in Japan - 2018. Cancer Information Service NCC.
(Japan). simplehttps://ganjoho.jp/en/professional/statistics/brochure/2018_en.htmlJune
26–2020
|
|
3
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group, : Phase III Trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group Study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
du Bois A, Lück HJ, Meier W, Adams HP,
Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et
al: A randomized clinical trial of Cisplatin/paclitaxel versus
Carboplatin/paclitaxel as First-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanner B, Hasenclever D, Stern K,
Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB,
Gebhard S, et al: ErbB-3 predicts survival in ovarian cancer. J
Clin Oncol. 24:4317–4323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sheng Q, Liu X, Fleming E, Yuan K, Piao H,
Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, et al: An
activated ErbB3/NRG1 autocrine loop supports in vivo proliferation
in ovarian cancer cells. Cancer Cell. 17:298–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xue C, Liang F, Mahmood R, Vuolo M,
Wyckoff J, Qian H, Tsai KL, Kim M, Locker J, Zhang ZY and Segall
JE: ErbB3-dependent motility and intravasation in breast cancer
metastasis. Cancer Res. 66:1418–1426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reschke M, Mihic-Probst D, van der Horst
EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H and
Ullrich A: HER3 is a determinant for poor prognosis in melanoma.
Clin Cancer Res. 14:5188–5197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ledel F, Hallstrom M, Ragnhammar P,
Ohrling K and Edler D: HER3 expression in patients with primary
colorectal cancer and corresponding lymph node metastases related
to clinical outcome. Eur J Cancer. 50:656–662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Q, Zhang R, Yan H, Zhao P, Wu L, Wang
H, Li T and Cao B: Prognostic significance of HER3 in patients with
malignant solid tumors. Oncotarget. 8:67140–67151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amin DN, Campbell MR and Moasser MM: The
role of HER3, the unpretentious member of the HER family, in cancer
biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Simpson BJ, Weatherill J, Miller EP,
Lessells AM, Langdon SP and Miller WR: c-erbB-3 protein expression
in ovarian tumours. Br J Cancer. 71:758–762. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cirstea AE, Stepan AE, Margaritescu C,
Zavoi RE, Olimid DA and Simionescu CE: The immunoexpression of
EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom J
Morphol Embyol. 58:1269–1273. 2017.
|
|
15
|
Théret N, Musso O, Campion JP, Turlin B,
Loréal O, L'Helgoualc'h A and Clément B: Overexpression of matrix
metalloproteinase-2 and tissue inhibitor of matrix
metalloproteinase-2 in liver from patients with gastrointestinal
adenocarcinoma and no detectable metastasis. Int J Cancer.
74:426–432. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanner B, Hengstler JG, Luch A, Meinert R,
Kreutz E, Arand M, Wilkens C, Hofmann M, Oesch F, Knapstein PG and
Becker R: C-myc mRNA expression in epithelial ovarian carcinomas in
relation to estrogen receptor status, metastatic spread, survival
time, FIGO stage, and histologic grade and type. Int J Gynecol
Pathol. 17:66–74. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hengstler JG, Pilch H, Schmidt M,
Dahlenburg H, Sagemüller J, Schiffer I, Oesch F, Knapstein PG,
Kaina B and Tanner B: Metallothionein expression in ovarian cancer
in relation to histopathological parameters and molecular markers
of prognosis. Int J Cancer. 95:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bezler M, Hengstler JG and Ullrich A:
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances
apoptosis of ovarian cancer cells. Mol Oncol. 6:516–529. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartley AN, Washington MK, Ventura CB,
Ismaila N, Colasacco C, Benson AB III, Carrato A, Gulley ML, Jain
D, Kakar S, et al: HER2 Testing and clinical decision making in
gastroesophageal adenocarcinoma: Guideline from the college of
american pathologists, american society for clinical pathology, and
american society of clinical oncology. Arch Pathol Lab Med.
140:1345–1363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mishra R, Patel H, Alanazi S, Yuan L and
Garrett JT: HER3 signaling and targeted therapy in cancer. Oncol
Rev. 12:3552018.PubMed/NCBI
|
|
21
|
Black LE, Longo JF and Carroll SL:
Mechanisms of receptor Tyrosine-protein kinase ErbB-3 (ERBB3)
action in human neoplasia. Am J Pathol. 189:1898–1912. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu JF, Ray-Coquard I, Selle F, Poveda AM,
Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P,
et al: Randomized phase II trial of seribantumab in combination
with paclitaxel in patients with advanced platinum-resistant or
-refractory ovarian cancer. J Clin Oncol. 34:4345–4353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kogawa T, Yonemori K, Masuda N, Takahashi
S, Takahashi M, Iwase H, Nakayama T, Saeki T, Toyama T, Takano T,
et al: Single agent activity of U3-1402, a HER3-targeting
antibody-drug conjugate, in breast cancer patients: Phase 1 dose
escalation study. J Clin Oncol. 36 (Suppl 15):S25122018. View Article : Google Scholar
|
|
24
|
Janne PA, Yu HA, Johnson ML, Steuer CE,
Vigliotti M, Iacobucci C, Chen S, Yu C and Sellami DB: Safety and
preliminary antitumor activity of U3-1402: A HER3-targeted antibody
drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 37
(Suppl 15):S90102019. View Article : Google Scholar
|
|
25
|
Mizuno M, Kikkawa F, Shibata K, Kajiyama
H, Ino K, Kawai M, Nagasaka T and Nomura S: Long-term follow-up and
prognostic factor analysis in clear cell adenocarcinoma of the
ovary. J Surg Oncol. 94:138–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crotzer DR, Sun CC, Coleman RL, Wolf JK,
Levenback CF and Gershenson DM: Lack of effective systemic therapy
for recurrent clear cell carcinoma of the ovary. Gynecol Oncol.
105:404–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takano M, Sugiyama T, Yaegashi N, Sakuma
M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, et al:
Low response rate of second-line chemotherapy for recurrent or
refractory clear cell carcinoma of the ovary: A retrospective Japan
clear cell carcinoma study. Int J Gynecol Cancer. 18:937–942. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao Z, Wu X, Yen L, Sweeney C and Carraway
KL III: Neuregulin-induced ErbB3 downregulation is mediated by a
protein stability cascade involving the E3 ubiquitin ligase Nrdp1.
Mol Cell Biol. 27:2180–2188. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sak MM, Breen K, Ronning SB, Pedersen NM,
Bertelsen V, Stang E and Madshus IH: The oncoprotein ErbB3 is
endocytosed in the absence of added ligand in a clathrin-dependent
manner. Carcinogenesis. 33:1031–1039. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ocana A, Vera-Badillo F, Seruga B,
Templeton A, Pandiella A and Amir E: HER3 overexpression and
survival in solid tumors: A meta-analysis. J Natl Cancer Inst.
105:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsuda H, Kurosumi M, Umemura S, Yamamoto
S, Kobayashi T and Osamura RY: HER2 testing on core needle biopsy
specimens from primary breast cancers: Interobserver
reproducibility and concordance with surgically resected specimens.
BMC Cancer. 10:5342010. View Article : Google Scholar : PubMed/NCBI
|
